Verve Therapeutics, Inc. () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1287805,
    "name": "Verve Therapeutics, Inc.",
    "stock_name": "Verve Therapeutics, Inc.",
    "full_name": "Verve Therapeutics, Inc.",
    "name_url": "stocks-analysis/verve-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "11.13",
    "chg": 0.03,
    "chgp": "0.27%",
    "dir": 1,
    "prev_price": "11.10",
    "mcapval": "993.66",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US92539P1012",
    "curr_date": "Jul 24",
    "curr_time": "",
    "bse_nse_vol": "11.11 M",
    "exc_status": "Active",
    "traded_date": "Jul 24, 2025",
    "traded_date_str": "2025 07 24",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/verve-therapeutics-inc-1287805-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Verve Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-verve-therapeutics-inc-technically-bullish-or-bearish-3547905",
        "imagepath": "",
        "date": "2025-09-20 20:05:40",
        "description": "As of 1 July 2025, the technical trend for Verve Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating some positive momentum. However, the RSI readings are bearish for both weekly and monthly periods, suggesting weakness in price strength. The Bollinger Bands are bullish weekly and mildly bullish monthly, supporting a positive outlook. Daily moving averages are bullish, and the OBV is bullish for both weekly and monthly periods, indicating accumulation. Conversely, the KST shows a bullish weekly but bearish monthly stance, and Dow Theory indicates a mildly bearish weekly trend with no trend monthly.\n\nIn terms of performance, Verve Therapeutics has outperformed the S&P 500 year-to-date with a return of 97.34% compared to 12.22%, and over the past year with a return of 57.2% against 17.14%. However, it has significantly..."
      },
      {
        "title": "Is Verve Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-verve-therapeutics-inc-overvalued-or-undervalued-3544125",
        "imagepath": "",
        "date": "2025-09-20 18:38:30",
        "description": "As of 2 March 2023, the valuation grade for Verve Therapeutics, Inc. has moved from does not qualify to risky, indicating a higher level of uncertainty regarding its valuation. The company appears to be overvalued given its negative financial metrics, including a Price to Book Value of 1.17, an EV to Sales ratio of 1.12, and a troubling ROE of -38.58%. Comparatively, peers such as ADMA Biologics, Inc. have a fair valuation with a P/E of 18.56, while Kymera Therapeutics, Inc. shows a risky valuation with a P/E of -11.23, highlighting the challenges Verve faces in the market.\n\nIn terms of recent performance, Verve Therapeutics has outperformed the S&P 500 with a year-to-date return of 97.34% compared to the index's 12.22%, although it has struggled over the longer term with a three-year return of -63.64% versus the S&P 500's 70.41%. This mixed performance further complicates the valuation narrative, suggestin..."
      }
    ],
    "total": 6,
    "sid": "1287805",
    "stock_news_url": "https://www.marketsmojo.com/news/verve-therapeutics-inc-1287805"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Verve Therapeutics, Inc. technically bullish or bearish?

2025-09-20 20:05:40

As of 1 July 2025, the technical trend for Verve Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating some positive momentum. However, the RSI readings are bearish for both weekly and monthly periods, suggesting weakness in price strength. The Bollinger Bands are bullish weekly and mildly bullish monthly, supporting a positive outlook. Daily moving averages are bullish, and the OBV is bullish for both weekly and monthly periods, indicating accumulation. Conversely, the KST shows a bullish weekly but bearish monthly stance, and Dow Theory indicates a mildly bearish weekly trend with no trend monthly. In terms of performance, Verve Therapeutics has outperformed the S&P 500 year-to-date with a return of 97.34% compared to 12.22%, and over the past year with a return of 57.2% against 17.14%. However, it has significantly...

Is Verve Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:38:30

As of 2 March 2023, the valuation grade for Verve Therapeutics, Inc. has moved from does not qualify to risky, indicating a higher level of uncertainty regarding its valuation. The company appears to be overvalued given its negative financial metrics, including a Price to Book Value of 1.17, an EV to Sales ratio of 1.12, and a troubling ROE of -38.58%. Comparatively, peers such as ADMA Biologics, Inc. have a fair valuation with a P/E of 18.56, while Kymera Therapeutics, Inc. shows a risky valuation with a P/E of -11.23, highlighting the challenges Verve faces in the market. In terms of recent performance, Verve Therapeutics has outperformed the S&P 500 with a year-to-date return of 97.34% compared to the index's 12.22%, although it has struggled over the longer term with a three-year return of -63.64% versus the S&P 500's 70.41%. This mixed performance further complicates the valuation narrative, suggestin...

View All News